Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically or cytologically confirmed advanced HCC~* No previous systematic treatment for HCC~* Have at least one measurable lesion (in accordance with RECIST v1.1)~* BCLC stage B or C, and not suitable for surgical or local therapy, or has progressed following surgical and/or local therapy~* ECOG-PS score 0 or 1~* Child-Pugh Class: Grade A~* Life Expectancy of at least 12 weeks~* Subjects with HBV infection: HBV DNA\<500 IU/ml or \< 2500 copy/mL, and have received anti-HBV therapy for at least 14 days prior to enrollment in the study~* Subjects with HCV-RNA(+) must receive antiviral therapy~* Adequate organ function~Exclusion Criteria:~* Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except HCC within 5 years or simultaneously~* Moderate-to-severe ascites with clinical symptoms~* History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage~* Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment~* Known genetic or acquired hemorrhage or thrombotic tendency~* Thrombosis or thromboembolic event within 6 months prior to the start of study treatment~* Cardiac clinical symptom or disease that is not well controlled~* Hypertension that can not be well controlled through antihypertensive drugs~* Factors to affect oral administration~* History of hepatic encephalopathy~* Previous or current presence of metastasis to central nervous system~* HIV infection~* Combined hepatitis B and hepatitis C co-infection~* Be ready for or previously received organ or allogenic bone marrow transplantation~* Interstitial lung disease that is symptomatic or may interfere with the detection and management of suspected drug-related pulmonary toxicity~* Active known, or suspected autoimmune disease~* Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of first administration of study treatment~* Use of potent CYP3A4 inducers or inhibitors within 2 weeks prior to the signature of ICF~* Known history of serious allergy to any monoclonal antibody or targeted anti-angiogenic drug~* Severe infection within 4 weeks prior to the start of study treatment~* Palliative radiotherapy for non-target lesions to control symptoms is allowed, but it must be completed at least 2 weeks prior to the start of study treatment~* Treatment of other investigational product(s) within 28 days prior to the start of study treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SHR-1210 (Type: EXPERIMENTAL): SHR-1210+Apatinib
- Control (Type: ACTIVE_COMPARATOR): Sorafenib

Based on this trial design, predict the completion outcome and termination type (if applicable).